Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance

Wenyong W. Zhang, Jorge E. Cortes, Hui Yao, Li Zhang, Neelima G. Reddy, Elias Jabbour, Hagop M. Kantarjian, Dan Jones

Research output: Contribution to journalArticle

Abstract

Purpose: A subset of patients with chronic myelogenous leukemia (CML) do not respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate. Such primary imatinib resistance is distinguished from secondary resistance which reemerges after attainment of cytogenetic remission. Patients and Methods: We studied gene expression patterns in total WBCs using a panel of 21 genes previously implicated in TKI handling, resistance, or progression comparing patients who had newly diagnosed TKI-naive CML that had optimal (n = 41), or suboptimal (n = 7) responses to imatinib, or primary resistance (n = 20). Expression patterns were compared to those in secondary TKI-resistant chronic phase CML without ABL1 kinase domain mutations (n = 29), and to lymphoid (n = 15) or myeloid blast phase disease (n = 12). Results: Fifteen genes in the panel distinguished blast phase from chronic phase disease, and 12 genes distinguished newly diagnosed CML from TKI-resistant CML without ABL1 kinase domain mutations, but only a single gene, prostaglandin-endoperoxide synthase 1/cyclooxgenase 1 (PTGS1/COX1; P = .005), differentiated imatinib-responsive from primary imatinib-resistant CML. The association of primary imatinib resistance with higher transcript levels of the drug metabolism gene PTGS1 was confirmed in a separate data set of 68 newly diagnosed, imatinib-treated CML (P = .008). In contrast, up to 11 different genes were identified in a multivariate model that optimally discriminated secondary imatinib resistance lacking ABL1 kinase domain mutation from imatinib-responsive cases, likely related to the more complex pathogenesis of secondary resistance. Conclusion: Gene expression profiling of CML at diagnosis for PTGS1 may be useful in predicting imatinib response and in selecting alternate therapy.

Original languageEnglish (US)
Pages (from-to)3642-3649
Number of pages8
JournalJournal of Clinical Oncology
Volume27
Issue number22
DOIs
StatePublished - Aug 1 2009
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Genes
Blast Crisis
Phosphotransferases
Mutation
Imatinib Mesylate
Leukemia, Myeloid, Chronic Phase
Gene Expression Profiling
Prostaglandin-Endoperoxide Synthases
Cytogenetics
Chronic Disease
Gene Expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. / Zhang, Wenyong W.; Cortes, Jorge E.; Yao, Hui; Zhang, Li; Reddy, Neelima G.; Jabbour, Elias; Kantarjian, Hagop M.; Jones, Dan.

In: Journal of Clinical Oncology, Vol. 27, No. 22, 01.08.2009, p. 3642-3649.

Research output: Contribution to journalArticle

Zhang, Wenyong W. ; Cortes, Jorge E. ; Yao, Hui ; Zhang, Li ; Reddy, Neelima G. ; Jabbour, Elias ; Kantarjian, Hagop M. ; Jones, Dan. / Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 22. pp. 3642-3649.
@article{12b88be74c3744888993e3d57b017c27,
title = "Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance",
abstract = "Purpose: A subset of patients with chronic myelogenous leukemia (CML) do not respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate. Such primary imatinib resistance is distinguished from secondary resistance which reemerges after attainment of cytogenetic remission. Patients and Methods: We studied gene expression patterns in total WBCs using a panel of 21 genes previously implicated in TKI handling, resistance, or progression comparing patients who had newly diagnosed TKI-naive CML that had optimal (n = 41), or suboptimal (n = 7) responses to imatinib, or primary resistance (n = 20). Expression patterns were compared to those in secondary TKI-resistant chronic phase CML without ABL1 kinase domain mutations (n = 29), and to lymphoid (n = 15) or myeloid blast phase disease (n = 12). Results: Fifteen genes in the panel distinguished blast phase from chronic phase disease, and 12 genes distinguished newly diagnosed CML from TKI-resistant CML without ABL1 kinase domain mutations, but only a single gene, prostaglandin-endoperoxide synthase 1/cyclooxgenase 1 (PTGS1/COX1; P = .005), differentiated imatinib-responsive from primary imatinib-resistant CML. The association of primary imatinib resistance with higher transcript levels of the drug metabolism gene PTGS1 was confirmed in a separate data set of 68 newly diagnosed, imatinib-treated CML (P = .008). In contrast, up to 11 different genes were identified in a multivariate model that optimally discriminated secondary imatinib resistance lacking ABL1 kinase domain mutation from imatinib-responsive cases, likely related to the more complex pathogenesis of secondary resistance. Conclusion: Gene expression profiling of CML at diagnosis for PTGS1 may be useful in predicting imatinib response and in selecting alternate therapy.",
author = "Zhang, {Wenyong W.} and Cortes, {Jorge E.} and Hui Yao and Li Zhang and Reddy, {Neelima G.} and Elias Jabbour and Kantarjian, {Hagop M.} and Dan Jones",
year = "2009",
month = "8",
day = "1",
doi = "10.1200/JCO.2008.19.4076",
language = "English (US)",
volume = "27",
pages = "3642--3649",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "22",

}

TY - JOUR

T1 - Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance

AU - Zhang, Wenyong W.

AU - Cortes, Jorge E.

AU - Yao, Hui

AU - Zhang, Li

AU - Reddy, Neelima G.

AU - Jabbour, Elias

AU - Kantarjian, Hagop M.

AU - Jones, Dan

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Purpose: A subset of patients with chronic myelogenous leukemia (CML) do not respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate. Such primary imatinib resistance is distinguished from secondary resistance which reemerges after attainment of cytogenetic remission. Patients and Methods: We studied gene expression patterns in total WBCs using a panel of 21 genes previously implicated in TKI handling, resistance, or progression comparing patients who had newly diagnosed TKI-naive CML that had optimal (n = 41), or suboptimal (n = 7) responses to imatinib, or primary resistance (n = 20). Expression patterns were compared to those in secondary TKI-resistant chronic phase CML without ABL1 kinase domain mutations (n = 29), and to lymphoid (n = 15) or myeloid blast phase disease (n = 12). Results: Fifteen genes in the panel distinguished blast phase from chronic phase disease, and 12 genes distinguished newly diagnosed CML from TKI-resistant CML without ABL1 kinase domain mutations, but only a single gene, prostaglandin-endoperoxide synthase 1/cyclooxgenase 1 (PTGS1/COX1; P = .005), differentiated imatinib-responsive from primary imatinib-resistant CML. The association of primary imatinib resistance with higher transcript levels of the drug metabolism gene PTGS1 was confirmed in a separate data set of 68 newly diagnosed, imatinib-treated CML (P = .008). In contrast, up to 11 different genes were identified in a multivariate model that optimally discriminated secondary imatinib resistance lacking ABL1 kinase domain mutation from imatinib-responsive cases, likely related to the more complex pathogenesis of secondary resistance. Conclusion: Gene expression profiling of CML at diagnosis for PTGS1 may be useful in predicting imatinib response and in selecting alternate therapy.

AB - Purpose: A subset of patients with chronic myelogenous leukemia (CML) do not respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate. Such primary imatinib resistance is distinguished from secondary resistance which reemerges after attainment of cytogenetic remission. Patients and Methods: We studied gene expression patterns in total WBCs using a panel of 21 genes previously implicated in TKI handling, resistance, or progression comparing patients who had newly diagnosed TKI-naive CML that had optimal (n = 41), or suboptimal (n = 7) responses to imatinib, or primary resistance (n = 20). Expression patterns were compared to those in secondary TKI-resistant chronic phase CML without ABL1 kinase domain mutations (n = 29), and to lymphoid (n = 15) or myeloid blast phase disease (n = 12). Results: Fifteen genes in the panel distinguished blast phase from chronic phase disease, and 12 genes distinguished newly diagnosed CML from TKI-resistant CML without ABL1 kinase domain mutations, but only a single gene, prostaglandin-endoperoxide synthase 1/cyclooxgenase 1 (PTGS1/COX1; P = .005), differentiated imatinib-responsive from primary imatinib-resistant CML. The association of primary imatinib resistance with higher transcript levels of the drug metabolism gene PTGS1 was confirmed in a separate data set of 68 newly diagnosed, imatinib-treated CML (P = .008). In contrast, up to 11 different genes were identified in a multivariate model that optimally discriminated secondary imatinib resistance lacking ABL1 kinase domain mutation from imatinib-responsive cases, likely related to the more complex pathogenesis of secondary resistance. Conclusion: Gene expression profiling of CML at diagnosis for PTGS1 may be useful in predicting imatinib response and in selecting alternate therapy.

UR - http://www.scopus.com/inward/record.url?scp=68949106066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949106066&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.19.4076

DO - 10.1200/JCO.2008.19.4076

M3 - Article

C2 - 19506164

AN - SCOPUS:68949106066

VL - 27

SP - 3642

EP - 3649

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 22

ER -